Ito H - Search Results

1

Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.

Onishi H, Yamaguchi M, Kuriyama K, Tsukamoto T, Ishigame K, Ichikawa T, Aoki S, Yoshikawa T, Araki T, Nambu A, Araki T, Hashi A, Yasumizu T, Hoshi K, Ito H. Onishi H, et al. Among authors: ito h. Cancer J Sci Am. 2000 Jan-Feb;6(1):40-5. Cancer J Sci Am. 2000. PMID: 10696738 Clinical Trial.

2

Prognosis of patients with T4 prostate carcinoma.

Furuya Y, Akakura K, Ichikawa T, Ito H. Furuya Y, et al. Among authors: ito h. Int J Urol. 1999 Apr;6(4):192-5. doi: 10.1046/j.1442-2042.1999.06447.x. Int J Urol. 1999. PMID: 10226837 Free article.

3

Radiotherapy for local progression in patients with hormone-refractory prostate cancer.

Furuya Y, Akakura K, Akimoto S, Ichikawa T, Ito H. Furuya Y, et al. Among authors: ito h. Int J Urol. 1999 Apr;6(4):187-91. doi: 10.1046/j.1442-2042.1999.06442.x. Int J Urol. 1999. PMID: 10226836 Free article.

4

External beam radiation monotherapy for prostate cancer.

Akakura K, Furuya Y, Suzuki H, Komiya A, Ichikawa T, Igarashi T, Tanaka M, Murakami S, Ito H. Akakura K, et al. Among authors: ito h. Int J Urol. 1999 Aug;6(8):408-13. doi: 10.1046/j.1442-2042.1999.00082.x. Int J Urol. 1999. PMID: 10466453 Free article.

5

Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer.

Furuya Y, Akakura K, Tanaka M, Ichikawa T, Igarashi T, Murakami S, Ito H. Furuya Y, et al. Among authors: ito h. Int J Urol. 2001 May;8(5):222-6. doi: 10.1046/j.1442-2042.2001.00288.x. Int J Urol. 2001. PMID: 11328422 Free article.

6

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer.

Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, Igarashi T, Ito H. Imamoto T, et al. Among authors: ito h. Endocr J. 2001 Oct;48(5):573-8. doi: 10.1507/endocrj.48.573. Endocr J. 2001. PMID: 11789562 Free article.

7

Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment.

Furuya Y, Akakura K, Tobe T, Ichikawa T, Igarashi T, Ito H. Furuya Y, et al. Among authors: ito h. Int Urol Nephrol. 2001;32(4):659-63. doi: 10.1023/a:1014410026495. Int Urol Nephrol. 2001. PMID: 11989560

8

Clinical significance of pulmonary metastases in stage D2 prostate cancer patients.

Nakamachi H, Suzuki H, Akakura K, Imamoto T, Ueda T, Ishihara M, Furuya Y, Ichikawa T, Igarashi T, Ito H. Nakamachi H, et al. Among authors: ito h. Prostate Cancer Prostatic Dis. 2002;5(2):159-63. doi: 10.1038/sj.pcan.4500573. Prostate Cancer Prostatic Dis. 2002. PMID: 12497007

9

Relationship of prostate-specific antigen levels to prostate volume and age in mass screening subjects.

Akimoto S, Ichikawa T, Ito H. Akimoto S, et al. Among authors: ito h. Urol Int. 1998 Aug;60(4):216-9. doi: 10.1159/000030257. Urol Int. 1998. PMID: 9701733

10

[Adrenocortical carcinoma].

Ichikawa T, Ito H. Ichikawa T, et al. Among authors: ito h. Nihon Rinsho. 2001 Nov;59 Suppl 7:393-400. Nihon Rinsho. 2001. PMID: 11808146 Review. Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,400 results

Search Page

Filters